DC9 — Redox control of inflammatory fibroblast priming

DC9 — Redox control of inflammatory fibroblast priming
DC9
Status: Closed
Supervisor
Professor Markus Hoffmann
Host Institution
University Hospital Schleswig-Holstein
City
Lübeck
Country
Germany

About this Project

This project will determine how oxidative stress and cellular metabolism maintain the pathogenic activation of synovial fibroblasts. It will test whether redox-modulating compounds can reverse inflammatory priming and restore a pro-resolving tissue state. The project is likely to involve experimental disease models in mice. Previous experience with mouse work would therefore be advantageous, although it is not an essential eligibility criterion.

Your profile and what you'll gain

Skills required

Background in cell biology, immunology, biochemistry, redox biology or molecular medicine; experience with cell culture, biochemical assays or microscopy is desirable.

Skills acquired

Reactive-oxygen-species measurement, glutathione and NRF2 pathway analysis, mitochondrial metabolism, fibroblast biology, 2D and 3D tissue models, synovial organoids, GPCR signalling and secretome analysis.

Eligibility Criteria

Before applying, candidates should ensure they meet the following eligibility criteria:

  • have a MSc degree in Life Sciences or obtain a MSc degree by October 2026
  • have completed a research internship with relevant expertise
  • have obtained high grades during his/her studies
  • be fluent in English (some countries may also require language certifications – this will be communicated to applicants following shortlisting)
  • applicant must not have resided in the country of the recruiting organisation for more than 12 months preceding the recruitment date. 
Supervisor
Professor Markus Hoffmann
• Closed
Host Institution
University Hospital Schleswig-Holstein
City
Lübeck
Country
Germany

Applications closed

Applications closed on 1 October 2026 and are now under review.

Share this project

15 doctoral projects

Find the project that fits you

  • DC1
    • Closed

    Cellular mechanisms of inflammation resolution in rheumatoid arthritis

    Supervisor: Professor Gerhard Krönke
    Institution: Charité – Universitätsmedizin Berlin
  • DC2
    • Closed

    Pro-resolving mechanisms in rheumatoid arthritis-associated cardiovascular disease

    Supervisor: Professor Catherine Godson
    Institution: University College Dublin
  • DC3
    • Closed

    Why does inflammation resolve in some forms of arthritis but persist in others?

    Supervisor: Dr Marc Dubourdeau
    Institution: AMBIOTIS
  • DC4
    • Closed

    Cardiac-cell metabolism in inflammatory arthritis

    Supervisor: Professor Mauro Perretti
    Institution: Queen Mary University of London
  • DC5
    • Closed

    Specialised pro-resolving mediators in cardiometabolic disease: human population studies

    Supervisor: Dr Marleen van Greevenbroek
    Institution: Maastricht University
  • DC6
    • Closed

    Macrophage-fibroblast mechanisms restoring joint immune homeostasis

    Supervisor: Professor Mariola Kurowska-Stolarska
    Institution: University of Glasgow
  • DC7
    • Closed

    MCTR3 signalling in synovial inflammation and tissue repair

    Supervisor: Professor Jesmond Dalli
    Institution: Queen Mary University of London
  • DC8
    • Closed

    Role of canonical–atypical chemokine receptor axis in resolution of inflammation

    Supervisor: Professor Martine Smit
    Institution: Vrije Universiteit Amsterdam
  • DC10
    • Closed

    Macrophage-derived specialised pro-resolving mediators in hypertension and cardiovascular damage

    Supervisor: Professor Ana Maria Briones
    Institution: Universidad Autónoma de Madrid
  • DC11
    • Closed

    Computational identification of therapeutic checkpoints and resolution-promoting agents

    Supervisor: Professor Olaf Wolkenhauer
    Institution: University of Rostock
  • DC12
    • Closed

    Small-molecule promoters of inflammation resolution

    Supervisor: Professor Trond V. Hansen
    Institution: University of Oslo
  • DC13
    • Closed

    Lipid-mediator class-switching drugs

    Supervisor: Professor Oliver Werz
    Institution: Friedrich Schiller University Jena
  • DC14
    • Closed

    Resomelagon in rheumatoid arthritis and cardiovascular comorbidities

    Supervisor: Professor Mauro Perretti
    Institution: Queen Mary University of London
  • DC15
    • Closed

    Specialised pro-resolving mediators as regulators of haematopoiesis in rheumatoid arthritis and cardiovascular disease

    Supervisor: Professor Jesmond Dalli
    Institution: Queen Mary University of London